Regulation
Regenxbio earns key FDA designation for DMD gene therapy
Regenxbio’s gene therapy RGX-202 gains an important regulatory marker as it looks to compete in a crowded field of DMD therapies.
Galera earns key FDA designation for pancreatic cancer drug
FDA ends clinical hold for Salarius’s Phase I/II pediatric cancer trial
Veru earns FDA go-ahead for new Phase III Covid-19 trial
FDA lifts partial hold on Inhibrx rare bone cancer trials
FDA greenlights Virios’s Phase III fibromyalgia program
